Journal Specialty Index  

Haematology

Topic	Issue
Safety of Blood Supply in Hong Kong	OCTOBER 2023 (2) ‧ VOL. 15 ‧ NO. 9
Iron-Restricted Erythropoiesis and Treatment With Intravenous Iron	OCTOBER 2023 (2) ‧ VOL. 15 ‧ NO. 9
Allogeneic Haematopoietic Stem Cell Transplantation	OCTOBER 2023 (2) ‧ VOL. 15 ‧ NO. 9
A Review on the Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma	MAY 2023 ‧ VOL. 15 ‧ NO. 3
Update on the Diagnosis and Treatment of Castleman Disease	OCTOBER 2022 ‧ VOL. 14 ‧ NO. 9
An Oral Selective Inhibitor of Exportin 1-Mediated Nuclear Export: Another FDA-Approved New Drug for Multiple Myeloma	OCTOBER 2022 ‧ VOL. 14 ‧ NO. 9
Evolution of Treatment of Acute Myeloid Leukaemia in the Past 50 Years	OCTOBER 2022 ‧ VOL. 14 ‧ NO. 9
Update on the Use of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Thrombosis	SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7
Coronavirus Vaccination in Haematological Patients in Hong Kong: The Knowns and Unknowns	SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7
Coronavirus Vaccination in Haematological Patients in Hong Kong: The Knowns and Unknowns	SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7
Update on the Treatment Strategies for Follicular Lymphoma	SEPTEMBER 2020 ‧ VOL. 12 ‧ NO. 8
Haematological Manifestations of COVID-19	SEPTEMBER 2020 ‧ VOL. 12 ‧ NO. 8
More Anti-Myeloma Agents in 2019/2020	SEPTEMBER 2020 ‧ VOL. 12 ‧ NO. 8
Cancer-Associated Thrombosis Treatment Decision Pathway	JANUARY 2020 ‧ VOL. 12 ‧ NO. 1
Myeloma: No Pain, More Gain	NOVEMBER 2019 ‧ VOL. 11 ‧ NO. 8
A Novel Antibody-Drug Conjugate Shows Promise for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	SEPTEMBER 2019 ‧ VOL. 11 ‧ NO. 6
Novel Targeted Therapies for Acute Myeloid Leukaemia	SEPTEMBER 2019 ‧ VOL. 11 ‧ NO. 6
Recognizing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors	SEPTEMBER 2019 ‧ VOL. 11 ‧ NO. 6
Update on the Management of Adult Acute Lymphoblastic Leukaemia	SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6
A Step Forward for the Management of Patients with Follicular Lymphoma?	SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agent (Venetoclax)	SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6
Curing Blood Cancers: No More Chemotherapy	NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7
Rituximab for Subcutaneous Use: New Route of Administration	SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6
Good's Syndrome: An Acquired Immunodeficiency Associated with Thymomas	SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6
Novel Oral Therapies for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia	SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6
Consensus Statements on the Prevention and Management of NOAC-Associated Bleeding in General Practice in Hong Kong	MARCH 2017 ‧ VOL. 9 ‧ NO. 2
Blood Cancers: No More Chemotherapy?	NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7
Overview of IgG4-related Disease: A Novel Entity	JULY 2016 ‧ VOL. 8 ‧ NO. 5
Hodgkin Lymphoma and Use of Brentuximab Vedotin in its Treatment	JANUARY 2016 ‧ VOL. 8 ‧ NO. 1
Lymphoma: New Age, New Drugs, New Survival	NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6
Update in the Management of Chronic Lymphocytic Leukaemia (CLL)	MAY 2015 ‧ VOL. 7 ‧ NO. 3
Improving Outcome and Quality of Life in Haematological Malignancies in the Elderly	NOVEMBER 2014 ‧ VOL. 6 ‧ NO. 6
Update in the Management of Mantle Cell Lymphoma	JUNE 2014 ‧ VOL. 6 ‧ NO. 3
Bendamustine: The Gift from Behind the Iron Curtain	JANUARY 2014 ‧ VOL. 6 ‧ NO. 1
Update on the Treatment of Chronic Myeloid Leukaemia	JANUARY 2014 ‧ VOL. 6 ‧ NO. 1
Perioperative Management of Patients on Novel Oral Anticoagulants	JANUARY 2014 ‧ VOL. 6 ‧ NO. 1
Supportive Care in Haematological Malignancies	DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7
Updates in Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia	MAY 2013 ‧ VOL. 5 ‧ NO. 3
Young Woman With Deep Vein Thrombosis	NOVEMBER 2012 ‧ VOL. 4 ‧ NO. 6
Update in the Management of Indolent Lymphoma	NOVEMBER 2011 ‧ VOL. 3 ‧ NO. 6
Treatment Options for Patients With Immune Thrombocytopenia	MAY 2010 ‧ VOL. 2 ‧ NO. 3
Update on Management of Myelodysplastic Syndromes	APRIL 2009 ‧ VOL. 1 ‧ NO. 2